These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20368067)

  • 21. Early pregnancy loss in women stimulated with gonadotropin-releasing hormone antagonist protocols according to oral contraceptive pill pretreatment.
    Bellver J; Albert C; Labarta E; Pellicer A
    Fertil Steril; 2007 May; 87(5):1098-101. PubMed ID: 17224146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
    Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
    Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should we advise patients undergoing IVF to start a cycle leading to a day 3 or a day 5 transfer?
    Kolibianakis EM; Zikopoulos K; Verpoest W; Camus M; Joris H; Van Steirteghem AC; Devroey P
    Hum Reprod; 2004 Nov; 19(11):2550-4. PubMed ID: 15298978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols for in vitro fertilisation and embryo transfer.
    Depalo R; Lorusso F; Palmisano M; Bassi E; Totaro I; Vacca M; Trerotoli P; Masciandaro P; Selvaggi L
    Gynecol Endocrinol; 2009 May; 25(5):328-34. PubMed ID: 19340626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
    Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients.
    Hompes PG; Broekmans FJ; Hoozemans DA; Schats R;
    Fertil Steril; 2008 Jun; 89(6):1685-93. PubMed ID: 17681325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substituting human chorionic gonadotropin by gonadotropin-releasing hormone agonist to trigger final follicular maturation, during controlled ovarian hyperstimulation, results in less systemic inflammation.
    Orvieto R; Zagatsky I; Yulzari-Roll V; La Marca A; Fisch B
    Gynecol Endocrinol; 2006 Aug; 22(8):437-40. PubMed ID: 17012105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of oral contraceptive pill for cycle scheduling prior to GnRH-antagonist protocol on IVF cycle parameters and pregnancy outcome.
    Pinkas H; Sapir O; Avrech OM; Ben-Haroush A; Ashkenzi J; Fisch B; Farhi J
    J Assist Reprod Genet; 2008 Jan; 25(1):29-33. PubMed ID: 18205037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development.
    Lainas TG; Petsas GK; Zorzovilis IZ; Iliadis GS; Lainas GT; Cazlaris HE; Kolibianakis EM
    Hum Reprod; 2007 Jun; 22(6):1540-6. PubMed ID: 17347165
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretreatment with oral contraceptive pills does not influence the pregnancy rate in the long leuprolide acetate protocol.
    Bozdag G; Esinler I; Yaralı H
    Gynecol Obstet Invest; 2012; 73(1):53-7. PubMed ID: 22133574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer.
    Merviel P; Antoine JM; Mathieu E; Millot F; Mandelbaum J; Uzan S
    Fertil Steril; 2004 Jul; 82(1):119-25. PubMed ID: 15236999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does the estradiol level on the day of human chorionic gonadotrophin administration have an impact on pregnancy rates in patients treated with rec-FSH/GnRH antagonist?
    Kyrou D; Popovic-Todorovic B; Fatemi HM; Bourgain C; Haentjens P; Van Landuyt L; Devroey P
    Hum Reprod; 2009 Nov; 24(11):2902-9. PubMed ID: 19671625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists.
    Kolibianakis EM; Zikopoulos K; Smitz J; Camus M; Tournaye H; Van Steirteghem AC; Devroey P
    Hum Reprod; 2004 Jul; 19(7):1525-9. PubMed ID: 15155603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of mild stimulation and conventional stimulation in ART outcome.
    Karimzadeh MA; Ahmadi S; Oskouian H; Rahmani E
    Arch Gynecol Obstet; 2010 Apr; 281(4):741-6. PubMed ID: 19834718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GnRH agonist and GnRH antagonist in intracytoplasmic injection cycles.
    Rashid MR; Ong FB; Omar MH; Ng SP; Nurshaireen A; Sharifah-Teh NS; Fazilah AH; Zamzarina MA
    Med J Malaysia; 2008 Jun; 63(2):113-7. PubMed ID: 18942295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial.
    Hauzman EE; Zapata A; Bermejo A; Iglesias C; Pellicer A; Garcia-Velasco JA
    Reprod Biol Endocrinol; 2013 Sep; 11():96. PubMed ID: 24074027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative study of luteal estradiol pre-treatment in GnRH antagonist protocols and in micro dose flare protocols for poor-responding patients.
    Davar R; Rahsepar M; Rahmani E
    Arch Gynecol Obstet; 2013 Jan; 287(1):149-53. PubMed ID: 22923150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of recombinant FSH dose adjustments on ovarian response in the second treatment cycle with IVF or ICSI in "standard" patients treated with 150 IU/day during the first cycle.
    Popovic-Todorovic B; Loft A; Ziebe S; Andersen AN
    Acta Obstet Gynecol Scand; 2004 Sep; 83(9):842-9. PubMed ID: 15315596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity.
    Orvieto R; Meltzer S; Rabinson J; Zohav E; Anteby EY; Nahum R
    Fertil Steril; 2008 Oct; 90(4):1294-6. PubMed ID: 18178197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.